Abstract
Management of COVID-19 patients with drug-induced liver lesions requires a comprehensive approach to treatment with correction of metabolic disorders and prevention of adverse events. We describe our experience with using Remaxol, a drug with hepatoprotective, antihypoxic, antioxidant, and cytoprotective effects. It is applied for hepatotropic support in COVID-19 patients receiving antiviral therapy. Intravenous infusions with Remaxol (400 mL) in comprehensive treatment of COVID-19 patients promoted normalization of liver function tests, which made it possible to continue antiviral therapy without dose correction and interruptions. Remaxol was well tolerated and caused no side effects; none of the patients required its cessation. Key words: hepatotoxicity, hepatoprotectors, Remaxol, COVID-19
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
